← Issue №12/ week of Sep 20, 2026/Colorectal

The influence of tumor side, sex, and screening on colon cancer stage and survival: a 25-year population-based study.

From GI Signals issue №12: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal retrospective · n=6,697 · Sep 14, 2026 · Dig Liver Dis · IF 4.2

The influence of tumor side, sex, and screening on colon cancer stage and survival: a 25-year population-based study.

New evidenceepidemiologycolorectal cancercolorectal cancer screeningdysplasia
Clinical takeawayConsider prioritizing FIT-based screening for older patients, particularly women, and men with advanced-stage disease, given the increased incidence and worse prognosis of right-sided colon cancer in these groups.
What it foundRight-sided colon cancer incidence increased with aging (p ≤ 0.001) and was associated with female sex (OR 1.40, 95% CI 1.27-1.54), advanced stage in men (node-positive: OR 1.54, 95% CI 1.17-2.02; metastatic: OR 1.47, 95% CI 1.06-2.03), and worse prognosis in men (HR 1.16, 95% CI 1.01-1.34) compared to left-sided colon cancer.
ContextConfirms and refines prior evidence on the divergent behavior of right- and left-sided colon cancer, emphasizing the role of tumor side, sex, and screening impact in stage and survival outcomes in older patients, women, and men with advanced-stage disease.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

Decision at stakethe choice of colorectal cancer screening modality

… Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. … The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Kayali S … Laghi L · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №12 Every paper GI Signals surfaces gets a page like this one. All issues